Georgene Hergenroeder, MD
Assistant Professor of Clinical Pediatrics (Pulmonary Medicine)
Attending Physician, Division of Pulmonary Medicine, Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
3500 Civic Center Blvd
Philadelphia, PA 19104
3500 Civic Center Blvd
Philadelphia, PA 19104
Education:
BA
University of Texas at Austin, 2013.
MD
Baylor College of Medicine, 2017.
Permanent linkBA
University of Texas at Austin, 2013.
MD
Baylor College of Medicine, 2017.
Selected Publications
Hergenroeder, G. Shenoy, A. : Cystic Fibrosis. Ferri’s Clinical Advisor 2026. Elsevier, Page: In press, 2026 Notes: Chapter.Georgene Hergenroeder MD and Deanna Green, MD, MHS : Executive Summary of the Cystic Fibrosis Foundation Evidence-based Guidelines for the Management of CRMS/CFSPID. Cystic Fibrosis Foundation Aug 2025 Notes: https://www.cff.org/medical-professionals/cystic-fibrosis-foundation-evidence-based-guidelines-management-crms-cfspid.
Georgene E. Hergenroeder, Kevin J. Psoter, Cynthia D. Brown, Josh Ostrenga, Christine Ford, Lisa Bendy, Bradley H. Rosen, Nell Meosky Luo, Connie Zhang, Kathryn A. Sabadosa, Clement L. Ren: Baseline Characteristics and Self-Reported Use of Chronic Daily Therapies of the Home Reported Outcomes With CFTR Modulator Therapy (HERO-2) Cohort. Pediatric Pulmonology 60(7): e71190, July 2025.
Georgene E Hergenroeder, Jonathan V Todd, Josh S. Ostrenga, Christopher H Goss, Raksha Jain, Wayne Morgan, Gregory S. Sawicki, Michael S Schechter, Elizabeth A Cromwell, Clement L Ren: Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele. Journal of Cystic Fibrosis 24(1): 135-141, January 2025.
Rosen BH, Psoter KJ, Sabadosa KA, Hergenroeder GE, Bendy LL, Luo NM, Zhang C, Ren CL, Brown CD: Using Real-World Research to Study the Impact of Chronic Daily Therapy Discontinuation in Cystic Fibrosis: The Home Reported Outcomes in Cystic Fibrosis 2 (HERO-2) Study Design. CHEST Pulmonary 2(4): 100080, Dec 2024.
Georgene E. Hergenroeder, Kevin J. Psoter, Cynthia D. Brown, Kathryn A. Sabadosa, Bradley H. Rosen, Lisa L. Bendy, Connie Zhang, Clement L. Ren: Outcomes of Diverse Recruitment Strategies in the Home Reported Outcomes with CFTR Modulator Therapy (HERO-2) Study. Journal of Cystic Fibrosis 23: 401-S402, Sep 2024.
Hergenroeder, G., Todd, J., Ostrenga, J., Goss, C., Jain, Raksha, Morgan, W., Sawicki, Gregory, Schechter, M., Cromwell, E., Ren, Clement L.: Real-world impact of elexacaftor/tezacaftor/ivacaftor on pulmonary and nutritional outcomes in people with cystic fibrosis. Journal of Cystic Fibrosis 23: S391-S392, Sep 2024.
G. Hergenroeder, JT, C. Goss, R. Jain, W. Morgan, G. Sawicki, M. Schechter, C. Ren. : Black and Hispanic people with cystic fibrosis (PwCF) and PwCF with high lung function are less likely to be prescribed elexacaftor-tezacaftor-ivacaftor despite having an eligible genotype. J Cystic Fibros 22: S205-206, Oct 2023.
G. Hergenroeder, K. Psoter, C. Brown, K. Sabadosa, L. Bendy, B. Rosen, N. Luo, C. Zhang, C. Ren: Clinical features associated with changes in chronic daily therapies in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor: Results from the Home Reported Outcomes 2 Study Journal of Cystic Fibrosis 22: S325, Oct 2023.
Hergenroeder, G.E., Faino, A.V., Cogen, J.D., Genatossio, A., McNamara, S., Pascual, M., & Hernandez, R.E: Seroprevalence and clinical characteristics of SARSCoV‐2 infection in children with cystic fibrosis. Pediatric Pulmonology 58(9): 2478-2486, Sep 2023.